Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Rivoceranib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Elevar Announces FDA Acceptance Of Rivoceranib For HCC Treatment
    Elevar Announces FDA Acceptance Of Rivoceranib For HCC Treatment

    21 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/21/2966150/0/en/Elevar-Therapeutics-Announces-FDA-Acceptance-of-New-Drug-Application-Resubmission-for-Rivoceranib-in-Combination-with-Camrelizumab-as-a-First-line-Systemic-Treatment-for-Unresectab.html

    GLOBENEWSWIRE
    21 Oct 2024
    Share Share
    Elevar Resubmits NDA For Camrelizumab Plus Rivoceranib In HCC
    Elevar Resubmits NDA For Camrelizumab Plus Rivoceranib In HCC

    23 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/23/2951315/0/en/Elevar-Therapeutics-Resubmits-New-Drug-Application-to-FDA-for-Combination-of-Camrelizumab-plus-Rivoceranib-as-First-Line-Treatment-Option-for-Unresectable-Hepatocellular-Carcinoma-.html

    GLOBENEWSWIRE
    23 Sep 2024
    Share Share
    Elevar Therapeutics Gets EU Orphan Drug Designation For HCC Therapy
    Elevar Therapeutics Gets EU Orphan Drug Designation For HCC Therapy

    01 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/01/2922906/0/en/Elevar-Therapeutics-Granted-Orphan-Medicinal-Product-Designation-by-the-European-Medicines-Agency-for-First-Line-Systemic-Therapy-for-Unresectable-Hepatocellular-Carcinoma.html

    GLOBENEWSWIRE
    01 Aug 2024
    Share Share
    FDA rejects Elevar, Hengrui's PD-1 combo
    FDA rejects Elevar, Hengrui's PD-1 combo

    18 May 2024

    // FIERCE PGARMA

    https://www.fiercepharma.com/pharma/fda-pd-1-combo-elevar-hengrui-camrelizumab-liver-cancer

    FIERCE PGARMA
    18 May 2024
    Share Share
    HLB fails to win US FDA's approval for Rivoceranib liver cancer drug
    HLB fails to win US FDA's approval for Rivoceranib liver cancer drug

    17 May 2024

    // KOREATIMES

    https://www.koreatimes.co.kr/www/nation/2024/05/129_374825.html

    KOREATIMES
    17 May 2024
    Share Share
    Jiangsu Hengrui and Elevar Therapeutics Announce Agreement for Camrelizumab
    Jiangsu Hengrui and Elevar Therapeutics Announce Agreement for Camrelizumab

    17 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/10/17/2761595/0/en/Jiangsu-Hengrui-Pharma-and-Elevar-Therapeutics-Announce-Global-Commercialization-Licensing-Agreement-for-PD-1-Inhibitor-Camrelizumab-in-Combination-with-Rivoceranib-for-uHCC.html

    GLOBENEWSWIRE
    17 Oct 2023
    Share Share